Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

Inclusion Criteria:

• Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
• Underwritten study consent
• No treatment with acetylcholinesterase inhibitors
• Mini-Mental-State Examination: 12-25 points
• Age: 50-80 Years
• Orale contraception for women of child-bearing age

Exclusion Criteria:

• Mental Disorders
• Other Diseases of the CNS
• Severe Illness
• Contraindication for MRI-Scan
• Contraindication for Galantamin (Reminyl retard®)
• Participation at other clinical trials